correction

Author: alexandriai168

coderdata/dataset.yml

@@ -218,223 +218,3 @@ datasets:
       - drug
       - drug descriptor
       - experiments
-figshare: https://api.figshare.com/v2/articles/28823159
-version: 2.1.0
-datasets:
-  beataml:
-    description: Beat acute myeloid leukemia (BeatAML) focuses on acute myeloid leukemia tumor data. Data includes drug response, proteomics, and transcriptomics datasets.
-    references:
-      - citation: Bottomly D, Long N, Schultz AR, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022;40(8):850-864.e9.
-        doi: https://doi.org/10.1016/j.ccell.2022.07.002
-      - citation: Pino JC, Posso C, Joshi SK, et al. Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia. Cell Rep Med. 2024;5(1):101359.
-        doi: https://doi.org/10.1016/j.xcrm.2023.101359
-    modalities:
-      - sample
-      - transcriptomics
-      - mutations
-      - proteomics
-      - drug
-      - drug descriptor
-      - experiments
-
-  bladderpdo:
-    description: Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. Data includes transcriptomics, mutations, copy number, and drug response data.
-    references:
-      - citation: Suk Hyung Lee, Wenhuo Hu, Justin T. Matulay, et al. Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. Cell. 2018;173(2):515-528.e17.
-        doi: https://doi.org/10.1016/j.cell.2018.03.017
-    modalities:
-      - sample
-      - transcriptomics
-      - mutations
-      - copy number
-      - drug
-      - drug descriptor
-      - experiments
-
-  ccle:
-    description: Cancer Cell Line Encyclopedia (CCLE).
-    references:
-      - citation: Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603-607.
-        doi: https://doi.org/10.1038/nature11003
-    modalities:
-      - sample
-      - transcriptomics
-      - proteomics
-      - mutations
-      - copy number
-      - drug
-      - drug descriptor
-      - experiments
-
-  cptac:
-    description: The Clinical Proteomic Tumor Analysis Consortium (CPTAC) project. Simplified and Unified Access to Cancer Proteogenomic Data.
-    references:
-      - citation: Lindgren CM, Adams DW, Kimball B, et al. Simplified and Unified Access to Cancer Proteogenomic Data. J Proteome Res. 2021;20(4):1902-1910.
-        doi: https://doi.org/10.1021/acs.jproteome.0c00919
-    modalities:
-      - sample
-      - transcriptomics
-      - proteomics
-      - mutations
-      - copy number
-
-  ctrpv2:
-    description: Cancer Therapeutics Response Portal version 2 (CTRPv2)
-    references:
-      - citation: Rees MG, Seashore-Ludlow B, Cheah JH, et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat Chem Biol. 2016;12(2):109-116.
-        doi: https://doi.org/10.1038/nchembio.1986
-      - citation: Seashore-Ludlow B, Rees MG, Cheah JH, et al. Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. Cancer Discov. 2015;5(11):1210-1223.
-        doi: https://doi.org/10.1158/2159-8290.CD-15-0235
-      - citation: Basu A, Bodycombe NE, Cheah JH, et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell. 2013;154(5):1151-1161.
-        doi: https://doi.org/10.1016/j.cell.2013.08.003
-    modalities:
-      - sample
-      - transcriptomics
-      - mutations
-      - copy number
-      - drug
-      - drug descriptor
-      - experiments
-
-  fimm:
-    description: Institute for Molecular Medicine Finland (FIMM) dataset.
-    references:
-      - citation: Mpindi JP, Yadav B, Östling P, et al. Consistency in drug response profiling. Nature. 2016;540(7631):E5-E6.
-        doi: https://doi.org/10.1038/nature20171
-      - citation: Pemovska T, Kontro M, Yadav B, et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 2013;3(12):1416-1429.
-        doi: https://doi.org/10.1158/2159-8290.CD-13-0350
-    modalities:
-      - sample
-      - transcriptomics
-      - drug
-      - drug descriptor
-      - experiments
-
-  hcmi:
-    description: Human Cancer Models Initiative (HCMI) encompasses numerous cancer types and includes cell line, organoid, and tumor data. Data includes transcriptomics, somatic mutation, and copy number datasets.
-    modalities:
-      - sample
-      - transcriptomics
-      - mutations
-      - copy number
-
-  mpnst:
-    description: Malignant Peripheral Nerve Sheath Tumor is a rare, aggressive sarcoma that affects peripheral nerves throughout the body.
-    references:
-      - citation: Dehner C, Moon CI, Zhang X, et al. Chromosome 8 gain is associated with high-grade transformation in MPNST. JCI Insight. 2021;6(6):e146351.
-        doi: https://doi.org/10.1172/jci.insight.146351
-    modalities:
-      - sample
-      - transcriptomics
-      - proteomics
-      - mutations
-      - copy number
-      - drug
-      - drug descriptor
-      - experiments
-
-  mpnstpdx:
-    description: Patient derived xenograft data for MPNST
-    modalities:
-      - sample
-      - transcriptomics
-      - drug
-      - drug descriptor
-      - experiments
-
-  nci60:
-    description: National Cancer Institute 60
-    references:
-      - citation: Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6(10):813-823.
-        doi: https://doi.org/10.1038/nrc1951
-    modalities:
-      - sample
-      - transcriptomics
-      - mutations
-      - proteomics
-      - drug
-      - drug descriptor
-      - experiments
-
-  pancpdo:
-    description: Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Data includes transcriptomics, mutations, copy number, and drug response data.
-    references:
-      - citation: Tiriac H, Belleau P, Engle DD, et al. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov. 2018;8(9):1112-1129.
-        doi: https://doi.org/10.1158/2159-8290.CD-18-0349
-    modalities:
-      - sample
-      - transcriptomics
-      - mutations
-      - copy number
-      - drug
-      - drug descriptor
-      - experiments
-
-  prism:
-    description: Profiling Relative Inhibition Simultaneously in Mixtures
-    references:
-      - citation: Corsello SM, Nagari RT, Spangler RD, et al. Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nat Cancer. 2020;1(2):235-248.
-        doi: https://doi.org/10.1038/s43018-019-0018-6
-      - citation: Yu C, Mannan AM, Yvone GM, et al. High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nat Biotechnol. 2016;34(4):419-423.
-        doi: https://doi.org/10.1038/nbt.3460
-    modalities:
-      - sample
-      - transcriptomics
-      - drug
-      - drug descriptor
-      - experiments
-
-  sarcpdo:
-    description: The landscape of drug sensitivity and resistance in sarcoma. Data includes transcriptomics, mutations, and drug response data.
-    references:
-      - citation: Al Shihabi A, Tebon PJ, Nguyen HTL, et al. The landscape of drug sensitivity and resistance in sarcoma. Cell Stem Cell. 2024;31(10):1524-1542.e4.
-        doi: https://doi.org/10.1016/j.stem.2024.08.010
-    modalities:
-      - sample
-      - transcriptomics
-      - mutations
-      - drug
-      - drug descriptor
-      - experiments
-
-  crcpdo:
-    description: Prospective derivation of a living organoid biobank of colorectal cancer patients.
-    references:
-      - citation: van de Wetering M, Francies HE, Francis JM, et al. Cell. 2015;161(4):933–945.
-        doi: https://doi.org/10.1016/j.cell.2015.03.053
-    modalities:
-      - sample
-      - transcriptomics
-      - mutations
-      - copy number
-      - drug
-      - drug descriptor
-      - experiments
-
-  liverpdo:
-    description: Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology.
-    references:
-      - citation: Ji S, Feng L, Fu Z, et al. Science Transl Med. 2023;15(706):eadg3358.
-        doi: https://doi.org/10.1126/scitranslmed.adg3358
-    modalities:
-      - sample
-      - transcriptomics
-      - mutations
-      - copy number
-      - drug
-      - drug descriptor
-      - experiments
-
-  novartispdx:
-    description: High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.
-    references:
-      - citation: Gao H, Korn JM, Ferretti S, et al. Nat Med. 2015;21(11):1318-1325.
-        doi: https://doi.org/10.1038/nm.3954
-    modalities:
-      - sample
-      - transcriptomics
-      - mutations
-      - copy number
-      - drug
-      - drug descriptor
-      - experiments